Florida sues Merck over Vioxx costs
Executive Summary
The Attorney General of Florida filed suit against Merck, claiming the company misrepresented and suppressed evidence about the risks of Vioxx (rofecoxib) and as a result its agencies suffered damages from purchasing the drug. The suit notes that the Florida Medicaid Program alone purchased at least $80 million of the pain reliever. An appeals court recently ruled that shareholders could pursue a securities class action alleging Merck defrauded investors by failing to disclose problems with Vioxx (1"The Pink Sheet," Sept. 15, 2008, p. 17)
You may also be interested in...
Appeals Court Reinstates Vioxx Securities Class Action Against Merck
A federal appeals court concluded that shareholders did not wait too long to bring a securities class action against Merck alleging the company defrauded investors by failing to disclose safety problems with its pain reliever Vioxx
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: